Research ArticleCancer

PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma

See allHide authors and affiliations

Science Translational Medicine  23 Sep 2020:
Vol. 12, Issue 562, eaay0152
DOI: 10.1126/scitranslmed.aay0152

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

A chink in cholangiocarcinoma’s armor

Cholangiocarcinoma is a bile duct cancer with limited therapeutic options and no established second-line treatment. In a screening assay looking for potential therapies to treat cholangiocarcinoma, Jiang et al. identified proteasome inhibitors, an established category of anticancer drugs. The authors also observed that a deficiency of the tumor suppressor PTEN, seen in many cancers including cholangiocarcinoma, sensitized the tumors to proteasome inhibitors. The researchers identified the mechanism underlying this interaction between PTEN and proteasome activity and assessed the therapeutic potential of proteasome inhibitors in mouse models as well as two patients with cholangiocarcinoma.

View Full Text

Stay Connected to Science Translational Medicine